A 2026 study in Nano Letters found that an experimental copper and selenium nanozyme protected insulin-making pancreatic cells from damage in lab tests. In diabetic mice, it lowered blood sugar about as well as metformin and protected the liver better, but it has not been tested in people.
Researchers tested a tiny experimental particle, called a nanozyme, that works like a cleanup crew for harmful molecules in the body. The particle also releases selenium, a mineral the body uses to protect cells from damage. In a 2026 study published in Nano Letters, the treatment appeared to shield insulin-making cells in the pancreas from a damaging form of cell death. In diabetic mice, it lowered blood sugar about as well as metformin, a common diabetes medicine, and it protected the liver from fat buildup better than metformin did. According to research reviewed by Gram, these results are promising, but they come from lab cells and mice. The treatment has not yet been tested in people, so it is not available as a diabetes treatment.
Key Statistics
A 2026 study published in Nano Letters found that an experimental copper-based nanozyme lowered blood sugar in diabetic mice about as well as metformin, a common diabetes medicine.
In the same 2026 Nano Letters study, the nanozyme protected against liver fat buildup better than metformin did in diabetic mice.
The 2026 Nano Letters study tested the nanozyme on pancreatic cells in the lab and in diabetic mice, but it did not include any human participants.
The Quick Take
- What they studied: Can a specially designed particle that cleans up harmful molecules and releases selenium protect the insulin-making cells in the pancreas from dying in type 2 diabetes?
- Who participated: The study used pancreatic cells grown in the lab and diabetic mice. The mice were given a high-fat diet and a drug called streptozotocin to cause diabetes. The exact number of mice was not specified in the study summary, and no people took part.
- Key finding: The experimental nanozyme lowered blood sugar in diabetic mice about as well as metformin, a standard diabetes drug. It also protected the liver from fat buildup better than metformin did. The study summary does not list exact percentages.
- What it means for you: This is early laboratory and animal research, so it does not mean you should change your diabetes care. It does point to a possible future approach that targets cell damage. Anyone with diabetes should keep following advice from their doctor, including any prescribed medicines.
The Research Details
The researchers built a particle that combines copper atoms with selenium. The copper part acts like a cleanup crew, breaking down reactive oxygen species, which are unstable molecules that damage cells when they build up. The selenium part is released mainly when cells are under heavy stress, so the protection is aimed at areas with the most damage.
First, the team tested the particle on pancreatic cells in the lab. They exposed the cells to high sugar levels and to a chemical that triggers ferroptosis, a type of cell death driven by iron and damaged fats. They then checked whether the particle reduced cell death, lowered fat damage, and kept the cell’s energy-producing structures intact.
Next, the team gave the particle to diabetic mice and compared it with metformin. They measured blood sugar, insulin resistance, energy use, and liver fat. This two-step approach, starting with cells and then moving to living animals, is a common way to test new treatments before human trials.
Testing in cells shows whether a treatment works at the level of individual cells and reveals how it might work. Testing in diabetic mice shows whether the effect holds up in a whole living body, where many systems interact. Comparing the treatment with metformin gives readers a familiar reference point, although a comparison in mice does not prove the same result would happen in people.
The study was published in Nano Letters, a peer-reviewed journal that is well respected in materials and nanoscience. Peer review means outside experts checked the work before publication. However, the summary does not report the number of mice or cells used, the statistical methods, or any safety data over time. Animal studies often do not translate directly to human health, so the results should be viewed as early-stage evidence.
What the Results Show
The particle appeared to reduce the damaging molecules that build up in pancreatic cells under high sugar conditions. It also reduced the iron-driven cell death called ferroptosis that was triggered in the lab. Cells treated with the particle showed less fat damage and kept their energy-producing structures, called mitochondria, in better shape.
In diabetic mice, the particle lowered blood sugar levels about as well as metformin. The researchers also reported improvements in insulin resistance, which is the body’s reduced response to insulin. Insulin resistance is a key problem in type 2 diabetes, so this is an important sign if it holds up in future studies.
The mice treated with the particle also burned more energy, according to the researchers. This suggests the treatment may affect how the body uses fuel, not just how it handles blood sugar.
The most notable result was in the liver. The particle protected against fatty liver changes better than metformin did. Fatty liver is common in people with type 2 diabetes, so this finding may matter if it is confirmed in people.
The researchers also looked at broader metabolic health, which covers how the body processes sugars and fats together. The particle improved several of these markers in the diabetic mice. These effects suggest the treatment may help more than one part of the metabolic problem at once, although the study summary provides limited detail on each measure.
Scientists have been studying ferroptosis as a possible driver of insulin-producing cell loss in type 2 diabetes for several years. Selenium and its enzyme partner GPX4 have also been linked to cell protection in earlier research. This study connects those ideas by delivering selenium directly where it is needed. Nanozymes, which are man-made particles that mimic natural enzymes, are a growing area of research, but most remain at the lab stage.
The study was conducted in cells and mice, not in people, so results may not carry over to human diabetes. The summary does not report sample sizes, dosing details, or how long the mice were followed. Long-term safety, including effects on the body’s organs over time, is not described. The comparison with metformin also relied on animal dosing, which may not match how people use the drug. Finally, the particle would need to be produced at scale and tested in clinical trials before it could be considered for patients.
The Bottom Line
Based on this single early-stage study, there is low confidence that this treatment will help people with diabetes. The findings are interesting and support further research into targeting cell damage in diabetes. No changes to diabetes care are recommended based on this research alone. Proven steps such as regular physical activity, balanced meals, and taking prescribed medicines remain the evidence-based approach.
People living with type 2 diabetes, fatty liver disease, or insulin resistance may find this research encouraging for the future. Researchers and drug developers working on pancreatic cell protection should pay close attention. People who are currently managing diabetes should not stop or change medicines based on this study, and they should talk with their doctor about any questions.
Lab and animal findings typically take many years to reach patients, if they succeed at all. Human safety and effectiveness trials usually come in several phases over a decade or more. Anyone hoping for a new treatment should expect a long wait, and current proven treatments remain the best choice for now.
Frequently Asked Questions
Can a nanozyme treat type 2 diabetes in humans?
Human testing has not been reported yet. A 2026 Nano Letters study tested the nanozyme only in lab cells and diabetic mice, where it lowered blood sugar about as well as metformin. Human clinical trials would be needed to confirm safety and benefit.
What is ferroptosis and why does it matter in diabetes?
Ferroptosis is a form of cell death driven by iron and damaged fats, along with harmful molecules called reactive oxygen species. Research suggests it may contribute to the loss of insulin-making beta cells in type 2 diabetes. The 2026 study found the nanozyme reduced this process in lab cells.
How does selenium help protect cells from damage?
Selenium is a mineral the body uses to build GPX4, an enzyme that neutralizes damaging fat molecules. In the 2026 mouse study, the nanozyme released selenium mainly when oxidative stress was high, which appeared to boost GPX4 levels where damage was occurring.
Does this nanozyme work better than metformin?
In diabetic mice, the nanozyme performed about as well as metformin for lowering blood sugar and improving insulin resistance. It protected the liver from fat buildup better than metformin did, according to the 2026 Nano Letters study. These animal results do not prove superiority in people.
Want to Apply This Research?
- Track fasting blood sugar and post-meal blood sugar readings at the same times each day, and log them in the app. Also record your daily steps and weekly minutes of activity so you can see how lifestyle changes affect your numbers over time.
- Use the app to set one small, realistic goal, such as a 10-minute walk after your largest meal. Pair this with a regular reminder to take prescribed medicines on schedule. Consistent habits have stronger evidence today than any experimental treatment.
- Review your logged blood sugar, activity, and meal patterns with your doctor at each checkup. Over several months, look for trends rather than single readings. Share updates from the app with your care team, and ask about any new research before making treatment changes.
This article summarizes early-stage laboratory and animal research published in Nano Letters. The treatment described has not been tested in humans and is not available as a medical treatment. This information is for education only and is not medical advice. Anyone with type 2 diabetes should talk with a qualified healthcare provider before making any changes to their treatment, medications, diet, or exercise routine.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.